FIT Biotech Oy
Press release 20.11.2018 at 09:30 EET
FIT Biotech in Sijoitus Invest event on 22 November 2018
FIT Biotech ("Company", FITBIO: FN Finland) is participating in Sijoitus Invest, an annual event for private investors, on Thursday 22 November 2018 at Messukeskus, Helsinki, Finland. Welcome to discuss with us and visit our stand 5 D 19 at 9-18. Come and listen to the presentation about "FIT Biotech as an investment" by Erkki Pekkarinen, CEO of FIT Biotech Oy, on Thursday 22 November at 14.30 on Sijoituslava.
Time: Thursday 22 November 2018 at 9-18
Location: FIT Biotech stand 5 D 19
Messukeskus, Helsinki, Finland
Presentation: FIT Biotech as an investment
CEO Erkki Pekkarinen
Thursday 22 November at 14.30-14.50
Sijoituslava
FIT BIOTECH OY
For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com
FIT Biotech in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies its GTU® technology in its development projects, which at the time include gene-based treatments, genetic vaccines and research collaboration. Application areas include cancer (gene therapy) and infectious diseases such as HIV.
FIT Biotech K-shares are listed on the First North Finland market maintained by Nasdaq Helsinki Ltd.
DISTRIBUTION:
Principal media
www.fitbiotech.com